250 related articles for article (PubMed ID: 31692922)
21. Gilteritinib: First Global Approval.
Dhillon S
Drugs; 2019 Feb; 79(3):331-339. PubMed ID: 30721452
[TBL] [Abstract][Full Text] [Related]
22. Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia.
McMahon CM; Perl AE
Expert Rev Clin Pharmacol; 2019 Sep; 12(9):841-849. PubMed ID: 31454267
[No Abstract] [Full Text] [Related]
23. The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation.
Tzogani K; Røshol H; Olsen HH; Aas IB; Dalhus ML; Håkonsen GD; Nilssen LS; Lindberg V; Økvist M; Bolstad B; Rogovska I; Karpova N; Enzmann H; Gisselbrecht C; Pignatti F
Oncologist; 2020 Jul; 25(7):e1070-e1076. PubMed ID: 32154636
[TBL] [Abstract][Full Text] [Related]
24. Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia.
Short NJ; Kantarjian H; Ravandi F; Daver N
Ther Adv Hematol; 2019; 10():2040620719827310. PubMed ID: 30800259
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.
Eguchi M; Minami Y; Kuzume A; Chi S
Biomedicines; 2020 Jul; 8(8):. PubMed ID: 32722298
[TBL] [Abstract][Full Text] [Related]
26. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
[TBL] [Abstract][Full Text] [Related]
27. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
[TBL] [Abstract][Full Text] [Related]
28. Phosphoproteome analyses reveal specific implications of Hcls1, p21-activated kinase 1 and Ezrin in proliferation of a myeloid progenitor cell line downstream of wild-type and ITD mutant Fms-like tyrosine kinase 3 receptors.
Habif G; Grasset MF; Kieffer-Jaquinod S; Kuhn L; Mouchiroud G; Gobert-Gosse S
J Proteomics; 2013 Jan; 78():231-44. PubMed ID: 23017497
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.
Yamatani K; Ai T; Saito K; Suzuki K; Hori A; Kinjo S; Ikeo K; Ruvolo V; Zhang W; Mak PY; Kaczkowski B; Harada H; Katayama K; Sugimoto Y; Myslinski J; Hato T; Miida T; Konopleva M; Hayashizaki Y; Carter BZ; Tabe Y; Andreeff M
Transl Oncol; 2022 Apr; 18():101354. PubMed ID: 35114569
[TBL] [Abstract][Full Text] [Related]
30. The GSK3β/Mcl-1 axis is regulated by both FLT3-ITD and Axl and determines the apoptosis induction abilities of FLT3-ITD inhibitors.
Qiu Y; Li Y; Chai M; Hua H; Wang R; Waxman S; Jing Y
Cell Death Discov; 2023 Feb; 9(1):44. PubMed ID: 36739272
[TBL] [Abstract][Full Text] [Related]
31. FLT3 mutations in acute myeloid leukemia cell lines.
Quentmeier H; Reinhardt J; Zaborski M; Drexler HG
Leukemia; 2003 Jan; 17(1):120-4. PubMed ID: 12529668
[TBL] [Abstract][Full Text] [Related]
32. Arsenic trioxide potentiates Gilteritinib-induced apoptosis in FLT3-ITD positive leukemic cells via IRE1a-JNK-mediated endoplasmic reticulum stress.
Hu X; Cai J; Zhu J; Lang W; Zhong J; Zhong H; Chen F
Cancer Cell Int; 2020; 20():250. PubMed ID: 32565734
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of FLT3 in AML: a focus on sorafenib.
Antar A; Otrock ZK; El-Cheikh J; Kharfan-Dabaja MA; Battipaglia G; Mahfouz R; Mohty M; Bazarbachi A
Bone Marrow Transplant; 2017 Mar; 52(3):344-351. PubMed ID: 27775694
[TBL] [Abstract][Full Text] [Related]
34. "FLipping" the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors.
Knight TE; Edwards H; Meshinchi S; Taub JW; Ge Y
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884458
[TBL] [Abstract][Full Text] [Related]
35. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
Weis TM; Marini BL; Bixby DL; Perissinotti AJ
Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
[TBL] [Abstract][Full Text] [Related]
36. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
Weir MC; Hellwig S; Tan L; Liu Y; Gray NS; Smithgall TE
PLoS One; 2017; 12(7):e0181178. PubMed ID: 28727840
[TBL] [Abstract][Full Text] [Related]
37. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
[No Abstract] [Full Text] [Related]
38. Gilteritinib Inhibits Glutamine Uptake and Utilization in
Zavorka Thomas ME; Lu X; Talebi Z; Jeon JY; Buelow DR; Gibson AA; Uddin ME; Brinton LT; Nguyen J; Collins M; Lodi A; Sweeney SR; Campbell MJ; Sweet DH; Sparreboom A; Lapalombella R; Tiziani S; Baker SD
Mol Cancer Ther; 2021 Nov; 20(11):2207-2217. PubMed ID: 34518298
[TBL] [Abstract][Full Text] [Related]
39. Integrin alphavbeta3 enhances β-catenin signaling in acute myeloid leukemia harboring Fms-like tyrosine kinase-3 internal tandem duplication mutations: implications for microenvironment influence on sorafenib sensitivity.
Yi H; Zeng D; Shen Z; Liao J; Wang X; Liu Y; Zhang X; Kong P
Oncotarget; 2016 Jun; 7(26):40387-40397. PubMed ID: 27248172
[TBL] [Abstract][Full Text] [Related]
40. Development of Gilteritinib-Based Chimeric Small Molecules that Potently Induce Degradation of FLT3-ITD Protein.
Ohoka N; Suzuki M; Uchida T; Tsuji G; Tsukumo Y; Yoshida M; Inoue T; Demizu Y; Ohki H; Naito M
ACS Med Chem Lett; 2022 Dec; 13(12):1885-1891. PubMed ID: 36518702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]